Elimination of CD4+ T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration

Journal of Investigative Dermatology

Volumn 115, Issue 6, 2000, Pages 1059-1064

  Nagai, Hiroshi ^a   Hara, Isao ^a   Horikawa, Tatsuya ^a   Oka, Masahiro ^a   Kamidono, Sadao ^a   Ichihashi, Masamitsu ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CD8 positive T lymphocyte; Cytokine; Gene therapy; Th1; Th2

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGENICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; GENE THERAPY; GENETIC TRANSFECTION; HAIR ROOT; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE DEPLETION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TUMOR GROWTH; TUMOR REGRESSION; VITILIGO;

EID: 0034526326     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2000.00156.x     Document Type: Article

References (48)

1. Anti-tumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells
2. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo
3. Cyclophosphamide (Cy) -facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing supressor T cells rather than by reducing tumour burden
4. Immunologically mediated regression of a murine lymphcma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity
5. Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of established tumors
6. Interleukin-12
7. Anti-tumor and antimetastatic activity of interleukin 12 against murine tumors
8. Serum antibodies in vitiligo patients
9. The prognostic significance of hypopigmentation in malignant melanoma
10. Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH 1 clones
11. Single-step method of RNA isolation by guanidium thiocyanate-chloroform extraction
12. Adoptive immunotherapy of syngeneic murine leukemia is enhanced by the combination of recombinant IFN-gamma and a tumor-specific cytotoxic T cell clone
13. Uveitis and vitiligo associated with BCG treatment for malignant melanoma
14. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF) -producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation
15. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization
16. Autoantibodies to tyrosinase: The bridge between melanoma and vitiligo
17. Treatment of established renal cell cancer by tumor cells engineered to secrete interleukin-4
18. Rejection of mouse melanoma elicited by local secretion of interleukin-2: Implicating macrophages without T cells or natural killer cells in tumor rejection
19. Implicating a role for immune recognition of self in tumor rejection: Passive immunization against the brown locus protein
20. Effect of tumor necrosis factor on cultured human melanoma cells
21. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy
22. Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay
23. Immunoregulatory effects of CD4+ T helper subsets in human melanoma
24. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes
25. Heterogeneity of cytokine secretion patterns and functions of helper T cells
26. The expanding universe of T-cell subsets: Th1, Th2 and more
27. Vitiligo in patients with metastatic melanoma: A good prognostic sign
28. Evidence for immunologic mechanisms in human vitiligo: Patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity
29. Radiation-induced, immunologically-mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells
30. Elimination of cycling CD4+ suppressor T cells with an antimitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma
31. Generation and decay of the immune response to a progressive fibrosarcoma. 1. Ly-1+2-supressor T cells down-regulate the generation of Ly-1-2+ effector T cells
32. Ly-1+2-supressor T cells down-regulate the generation of Ly-1-2+ effector T cells during progressive growth of P 815 mastocytoma
33. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy
34. A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells
35. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induce autoimmune vitiiigo and tumor cell destruction in mice: Requirement for CD4+ T lymphocytes
36. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery
37. Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo
38. Elimination of CD4+ T cells in mice bearing an advanced sarcoma augments the anti-tumor action of interleukin-2
39. Molecular Cloning
40. The tumorigenicity of IL-2 gene-transfected murine M-3D melanoma cells is determined by the magnitude and quality of the host defence reaction: Natural killer cells play a major role
41. Mechanisms of T cell-B cell interaction
42. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV 40 early region promoter
43. Experimental and clinical studies of cytokine gene-modified tumor cells
44. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector
45. Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in generation of T-helper cells type 1 and cytotoxic lymphocytes
46. T cell populations primed by hapten sensitization in contact sensitivity are distinguished by polarized patterns of cytokine production: Interferon gamma-producing (Tc1) effector CD8+ T cells and interleukin (IL) 4/IL-10-producing (Th2) negative regulatory CD4+ T cells
47. Interferon-gamma treatment of B16 melanoma cells; opposing effects for non-adaptive and adaptive immune defense and its reflection by metastatic spread